An unusual case of acquired angioedema associated with monoclonal gammopathies of uncertain significance
Main Article Content
Keywords
Angioedema, C1-INH, AAE, MGUS, laryngeal edema
Abstract
Acquired angioedema (AAE) is a rare disease due to the C1 esterase inhibitor (C1-INH) deficiency. Clinically, its symptoms are similar to hereditary angioedema (HAE) with hereditary C1-INH deficiency. Both conditions have the potential to cause upper airway obstruction, which can be fatal in clinical practice and thus require intense attention. Here, we’d like to discuss the clinical presentation, diagnosis and follow up of a special case of AAE associated with monoclonal gammopathies of unknown significance (MGUS) with recurrent upper airway obstruction. The patient was regularly followed up after being discharged from our ward. Measurements of C3–C4 levels were carried out by a hematological test. Due to the rarity of such a disease, especially in Chinese people, relevant diagnosis methods are missing in this patient, so the patient was only diagnosed with AAE-C1-INH associated with MGUS clinically. The latest follow up showed that he still underwent recurrent upper airway obstruction; thus, he remained in a tracheostomy state due to a lack of proper medication prophylaxis and died eventually. This unusual case reminds emergency physicians to pay attention to such disease during clinical practice, and relevant diagnosis method should be improved.
References
2. Banerji A, Sheffer AL. The spectrum of chronic angioedema. Allergy Asthma Proc. 2009;30(1):11–16. 10.2500/aap.2009.30.3188
3. Parikh NG, Yusin J, Klaustermeyer W. A unique case of delayed diagnosis of early onset acquired angioedema. Hypersensitivity. 2013;1:2. 10.7243/2052-594X-1-2
4. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin Immuno-pathol. 2005;27:286–298. 10.1007/s00281-005-0001-4
5. Jackson J, Sim RB, Whelan A, Feighery C. An IgG autoantibody which inactivates C1-inhibitor. Nature. 1986;323:722–724. 10.1038/323722a0
6. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med. 1987;316:1360–1366. 10.1056/NEJM198705283162202
7. Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis. 2019;14:65. 10.1186/s13023-019-1043-3
8. Kyle RA, Benson J, Larson D, Therneau T, Dispenzieri A, Iii LJM, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström’s macroglobulinemia. Clin. Lymphoma Myeloma. 2009;9:17–18. 10.3816/CLM.2009.n.002
9. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammo-pathy of undetermined significance. N Engl J Med. 2018;378: 241–249. 10.1056/NEJMoa1709974
10. Kristinsson SY, Björkholm M, Andersson TM-L, Eloranta S, Dickman PW, Goldin LR, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haemato-logy. 2009;94:1714–1720. 10.3324/haematol.2009.010066
11. Castelli R, Deliliers DL, Zingale LC, Pogliani EM, Cicardi M. Lymphoproliferative disease and acquired C1-inhibitor deficiency. Haematologica. 2007;92:716–718. 10.3324/haematol.10769
12. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol. 1994;93:870–876. 10.1016/0091-6749(94)90380-8
13. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602–616. 10.1111/all.12380
